**The primary driver of trader sentiment on broader marijuana rescheduling is the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude by July 15.** This proceeding, reset after an earlier stalled process, evaluates moving all cannabis from Schedule I to Schedule III following President Trump’s December 2025 executive order directing expedited rulemaking. In April 2026, the Department of Justice already placed FDA-approved marijuana products and state-licensed medical cannabis into Schedule III via final order, effective late April. The current hearing focuses on the remaining broader change, including recreational use, with selected participants largely opposing rescheduling. Any final rule would follow the hearing record and could face legal or procedural delays. Traders monitor hearing developments, participant filings, and potential agency action timelines for signals on whether full rescheduling occurs before year-end or in subsequent quarters.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено$791,987 Объем
31 мар. 2026 г.
30 сентября
14%
31 декабря
28%
$791,987 Объем
30 сентября
$0 Объем
14%
31 декабря
$182,416 Объем
28%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary driver of trader sentiment on broader marijuana rescheduling is the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude by July 15.** This proceeding, reset after an earlier stalled process, evaluates moving all cannabis from Schedule I to Schedule III following President Trump’s December 2025 executive order directing expedited rulemaking. In April 2026, the Department of Justice already placed FDA-approved marijuana products and state-licensed medical cannabis into Schedule III via final order, effective late April.
The current hearing focuses on the remaining broader change, including recreational use, with selected participants largely opposing rescheduling. Any final rule would follow the hearing record and could face legal or procedural delays. Traders monitor hearing developments, participant filings, and potential agency action timelines for signals on whether full rescheduling occurs before year-end or in subsequent quarters.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Открытие рынка: Feb 7, 2026, 5:04 PM ET
Объем
$791,987Дата окончания
31 мар. 2026 г.Открытие рынка
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**The primary driver of trader sentiment on broader marijuana rescheduling is the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude by July 15.** This proceeding, reset after an earlier stalled process, evaluates moving all cannabis from Schedule I to Schedule III following President Trump’s December 2025 executive order directing expedited rulemaking. In April 2026, the Department of Justice already placed FDA-approved marijuana products and state-licensed medical cannabis into Schedule III via final order, effective late April.
The current hearing focuses on the remaining broader change, including recreational use, with selected participants largely opposing rescheduling. Any final rule would follow the hearing record and could face legal or procedural delays. Traders monitor hearing developments, participant filings, and potential agency action timelines for signals on whether full rescheduling occurs before year-end or in subsequent quarters.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Объем
$791,987Дата окончания
31 мар. 2026 г.Открытие рынка
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**The primary driver of trader sentiment on broader marijuana rescheduling is the expedited DEA administrative hearing that began June 29, 2026, and was scheduled to conclude by July 15.** This proceeding, reset after an earlier stalled process, evaluates moving all cannabis from Schedule I to Schedule III following President Trump’s December 2025 executive order directing expedited rulemaking. In April 2026, the Department of Justice already placed FDA-approved marijuana products and state-licensed medical cannabis into Schedule III via final order, effective late April. The current hearing focuses on the remaining broader change, including recreational use, with selected participants largely opposing rescheduling. Any final rule would follow the hearing record and could face legal or procedural delays. Traders monitor hearing developments, participant filings, and potential agency action timelines for signals on whether full rescheduling occurs before year-end or in subsequent quarters.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы